The
p38 mitogen-activated protein kinase (MAPK) plays a critical role in the activation of inflammatory cells. Therefore, we investigated the antiinflammatory effects of a respirable p38alpha MAPK
antisense oligonucleotide (p38alpha-ASO) in a mouse
asthma model. A potent and selective p38alpha-ASO was characterized in vitro. Inhalation of aerosolized p38alpha-ASO using an
aerosol chamber dosing system produced measurable lung deposition of ASO and significant reduction of
ovalbumin (OVA-)-induced increases in total cells, eosinophils, and
interleukin 4 (IL-4),
IL-5, and
IL-13 levels in bronchoalveolar lavage fluid, and dose-dependent inhibition of
airway hyperresponsiveness in
allergen-challenged mice. Furthermore, inhaled p38alpha-ASO markedly inhibited OVA-induced lung tissue
eosinophilia and airway mucus hypersecretion. Quantitative polymerase chain reaction analysis of bronchoalveolar lavage fluid cells and peribronchial lymph node cells showed that p38alpha-ASO significantly reduced p38alpha MAPK
mRNA expression. Nose-only
aerosol exposure of mice verified the p38alpha-ASO-induced inhibition of OVA-induced
pulmonary eosinophilia, mucus hypersecretion, and
airway hyperresponsiveness. None of the effects of the p38alpha-ASO were produced by a six-base mismatched control
oligonucleotide. These findings demonstrate antisense pharmacodynamic activity in the airways after
aerosol delivery and suggest that a p38alpha MAPK ASO approach may have therapeutic potential for
asthma and other inflammatory
lung diseases.